Stadler R, Bratzke B, Mayer da Silva A, Orfanos C E
Universitäts-Hautklinik und Poliklinik, Klinikum Steglitz der Freien Universität Berlin.
Onkologie. 1988 Aug;11(4):166-76. doi: 10.1159/000216516.
Since 1980, disseminated Kaposi's sarcoma has been occurring in new epidemic proportions with a rapid clinical course in risk populations. Sixteen cases were under therapy and close surveillance from 1982 to 1986. Eight are still under therapy. In disseminated Kaposi's sarcoma with acquired immune deficiency syndrome (AIDS) our experience was encouraging. Following systemic, long-term treatment with recombinant alpha 2a interferon we observed complete remission of the lesions in 2 cases, partial remission and stabilization of the disease in 3 cases, at least temporary stabilization of the disease in 3 cases and progressive disease in 8 cases. Systemic rIFN-alpha 2a therapy was well tolerated; its long-term administration in patients with a relatively good immune status has an obviously beneficial effect on the course of Kaposi's sarcoma. In metastatic malignant melanoma Stage IV the results were only moderately encouraging. Regression of cutaneous metastases in 1 case and long-term stabilization of the disease in another patient point to antitumor activity of interferon in disseminated malignant melanoma. However, the administration of rIFN-alpha 2a in earlier stages appears more promising.
自1980年以来，播散性卡波西肉瘤在高危人群中呈新的流行态势，临床病程进展迅速。1982年至1986年期间，对16例患者进行了治疗和密切监测。其中8例仍在接受治疗。在伴有获得性免疫缺陷综合征（AIDS）的播散性卡波西肉瘤患者中，我们的经验令人鼓舞。在用重组α2a干扰素进行全身长期治疗后，我们观察到2例患者的病灶完全缓解，3例患者部分缓解且病情稳定，3例患者至少病情暂时稳定，8例患者病情进展。全身应用rIFN-α2a耐受性良好；在免疫状态相对良好的患者中长期给药对卡波西肉瘤病程有明显有益影响。在IV期转移性恶性黑色素瘤患者中，结果仅略显鼓舞人心。1例患者皮肤转移灶消退，另1例患者病情长期稳定，这表明干扰素对播散性恶性黑色素瘤具有抗肿瘤活性。然而，在疾病早期应用rIFN-α2a似乎更有前景。
